Hims & Hers Health, Amazon

BofA analyst Allen Lutz downgraded Hims & Hers to Underperform from Buy. Published first on TheFly – the ultimate source for ...
Hims & Hers (HIMS) fell 22% after Amazon (AMZN) announced it was entering the hair loss and erectile dysfunction treatment ...
Walt Disney’s earnings beat Wall Street estimates, Super Micro Computer extends losses, and Cisco posts fiscal first-quarter ...
Hims & Hers once again delivered a blowout quarter with surging revenue. Revenue soared 77% year over year to $401.6 million, ...
Hims & Hers introduced a new tracker to monitor shortages of GLP-1 weight loss and diabetes drugs, responding to the FDA's decision to end the compounded versions, Yahoo Finance reported Nov. 13.
Health and wellness platform Hims & Hers Health, Inc. (NYSE:HIMS), which has gained traction for its obesity-related ...
Hims & Hers Health, Inc.’s HIMS investors are reaping some gains from the stock of late. Shares of the San Francisco, ...
Hims & Hers Health, a telehealth company, is planning to offer a generic version of Novo Nordisk's diabetes drug, liraglutide ...